IFNB1 and myeloid sarcoma: The DMTs, including IFN-β, fingolimod, siponimod, teriflunomide, natalizumab, rituximab, ocrelizumab, and dimethyl fumarate, effectively reduce the recurrence in patients with MS (Bar-Or et al., 2014; Ciotti and Cross, 2018; Rae-Grant et al., 2018).